A MATRIXX Revolution? Is there a need to describe all adverse event reports in SEC filings of life sciences companies?
By Peter S. Reichertz
The U.S. Supreme Court has scheduled oral argument for January 10, 2011, in the case of Matrixx Initiatives et al v. Siracusano, Case Number 09-1156, on appeal from the decision of the Ninth Circuit in Siracusano v. Matrixx Initiatives, Inc., 585 F3d 1167 (9th Cir. 2008). The court granted certiorari on July 14, 2010.
